Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Century Therapeutics's Enterprise Value is $293.8 Mil.
Century Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-86.8 Mil. Therefore, Century Therapeutics's EV-to-OCF for today is -3.39.
The historical rank and industry rank for Century Therapeutics's EV-to-OCF or its related term are showing as below:
IPSC'
s EV-to-OCF Range Over the Past 10 Years
Min: -3.79 Med: 0.2 Max: 28.25
Current: -3.39
During the past 7 years, the highest EV-to-OCF of Century Therapeutics was 28.25. The lowest was -3.79. And the median was 0.20.
IPSC's EV-to-OCF is ranked worse than 51.95% of 1409
companies
in the Biotechnology industry
Industry Median: -3.68
vs IPSC: -3.39
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Century Therapeutics (NAS:IPSC) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Century Therapeutics's PE Ratio (TTM) for today is calculated as:
Century Therapeutics's share price for today is $2.07.
Century Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Century Therapeutics EV-to-OCF Related Terms
Century Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Century Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Century Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Century Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Century Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Century Therapeutics's EV-to-OCF falls into.
Century Therapeutics's current Enterprise Value is $293.8 Mil.
Century Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Century Therapeutics (IPSC) has a EV-to-OCF of -3.39 as of Aug. 24, 2026. According to the industry distribution chart, Century Therapeutics ranks #732 out of 1409 companies in the Biotechnology industry, placing it in the top 52%.
Is Century Therapeutics' EV-to-OCF too high?
Century Therapeutics' current EV-to-OCF is -3.39. Based on the distribution chart, Century Therapeutics ranks #732 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' EV-to-OCF compare to STRO and AVIR?
According to the Biotechnology industry distribution chart, Century Therapeutics ranks #732 out of 1409 companies for EV-to-OCF. This places Century Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Century Therapeutics's current EV-to-OCF is -3.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $39.83, compared to a current price of $2.07 — trading 94.8% below its estimated fair value. The current EV-to-OCF is -3.39. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current EV-to-OCF is -3.39 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Century Therapeutics (IPSC) Overvalued in 2026?
Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued.
The current stock price of $2.07 is trading 94.8% below its estimated GF Value™ of $39.83.
GuruFocus considers Century Therapeutics to be Possible Value Trap.
Key valuation signals for IPSC:
EV-to-OCF: -3.39
GF Value™: $39.83 vs. price of $2.07 (94.8% below fair value)
No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score
Get the complete analysis for IPSC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSC has been successfully added to your 
